## Albert Llado Plarrumani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4821128/publications.pdf

Version: 2024-02-01

116

all docs

104 3,933 31
papers citations h-index

116

docs citations

h-index g-index

116 6317
times ranked citing authors

133252

59

#	Article	IF	CITATIONS
1	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nature Genetics, 2010, 42, 234-239.	21.4	479
2	Neurodegenerative Disorder Risk in Idiopathic REM Sleep Behavior Disorder: Study in 174 Patients. PLoS ONE, 2014, 9, e89741.	2.5	407
3	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	10.2	175
4	Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. Annals of Neurology, 2017, 82, 419-428.	5 <b>.</b> 3	161
5	Increased Cortical Thickness and Caudate Volume Precede Atrophy in PSEN1 Mutation Carriers. Journal of Alzheimer's Disease, 2010, 22, 909-922.	2.6	136
6	Clinical features and <i>APOE</i> genotype of pathologically proven early-onset Alzheimer disease. Neurology, 2011, 76, 1720-1725.	1.1	123
7	Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimer's Disease: Potential and Limitations. Molecular Neurobiology, 2017, 54, 5550-5562.	4.0	119
8	Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid. Molecular and Cellular Proteomics, 2019, 18, 546-560.	3.8	115
9	Cerebrospinal Fluid Level of YKL-40 Protein in Preclinical and Prodromal Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, 901-908.	2.6	102
10	CSF sAPP $\hat{l}^2$ , YKL-40, and neurofilament light in frontotemporal lobar degeneration. Neurology, 2017, 89, 178-188.	1.1	100
11	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	10.2	97
12	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Acta Neuropathologica, 2014, 128, 397-410.	7.7	93
13	Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 1259-1272.	0.8	86
14	A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer's disease. Acta Neuropathologica, 2016, 132, 213-224.	7.7	83
15	Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2014, 4, 297-304.	1.3	82
16	White matter changes in preclinical Alzheimer's disease: a magnetic resonance imaging-diffusion tensor imaging study on cognitively normal older people with positive amyloid $\hat{l}^2$ protein 42 levels. Neurobiology of Aging, 2014, 35, 2671-2680.	3.1	72
17	Analysis of the <i>CHCHD10</i> gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Spain. Brain, 2015, 138, e400-e400.	7.6	56
18	CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD. Neurobiology of Aging, 2016, 38, 47-55.	3.1	54

#	Article	IF	Citations
19	Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 113.	6.2	54
20	Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A Multicenter Study in Spain. Journal of Alzheimer's Disease, 2014, 39, 719-726.	2.6	53
21	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease. Acta Neuropathologica, 2017, 134, 475-487.	7.7	53
22	Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomalâ€dominant Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 1251-1260.	0.8	47
23	Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias. Alzheimer's and Dementia, 2020, 16, 262-272.	0.8	47
24	CSF microRNA Profiling in Alzheimer's Disease: a Screening and Validation Study. Molecular Neurobiology, 2017, 54, 6647-6654.	4.0	45
25	Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy. Brain, 2019, 142, 1121-1133.	7.6	45
26	Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromes. Neurology, 2004, 63, 1947-1949.	1.1	40
27	Clinicopathological and genetic correlates of frontotemporal lobar degeneration and corticobasal degeneration. Journal of Neurology, 2008, 255, 488-494.	3.6	40
28	The <i>APOE</i> ε4 genotype modulates CSF YKLâ€40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 50-59.	2.4	36
29	Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. Neurobiology of Aging, 2014, 35, 2657.e13-2657.e19.	3.1	34
30	Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. Neurobiology of Aging, 2015, 36, 2005.e15-2005.e22.	3.1	34
31	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. Alzheimer's and Dementia, 2021, 17, 1329-1341.	0.8	34
32	Usefulness of Biomarkers in the Diagnosis and Prognosis of Early-Onset Cognitive Impairment. Journal of Alzheimer's Disease, 2014, 40, 919-927.	2.6	32
33	Serum Progranulin Levels in Patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease: Detection of GRN Mutations in a Spanish Cohort. Journal of Alzheimer's Disease, 2012, 31, 581-591.	2.6	31
34	Frontotemporal Dementia Caused by the P301L Mutation in <b> </b> the <b><i> MAPT</i></b> Gene: Clinicopathological Features of 13 Cases from the Same Geographical Origin in Barcelona, Spain. Dementia and Geriatric Cognitive Disorders, 2017, 44, 213-221.	1.5	31
35	Evolving brain structural changes in PSEN1 mutation carriers. Neurobiology of Aging, 2015, 36, 1261-1270.	3.1	30
36	Clinical and video-polysomnographic analysis of rapid eye movement sleep behavior disorder and other sleep disturbances in dementia with Lewy bodies. Sleep, 2019, 42, .	1.1	30

#	Article	IF	Citations
37	Hippocampal atrophy has limited usefulness as a diagnostic biomarker on the early onset Alzheimer's disease patients: A comparison between visual and quantitative assessment. Neurolmage: Clinical, 2019, 23, 101927.	2.7	29
38	Mechanisms of functional compensation, delineated by eigenvector centrality mapping, across the pathophysiological continuum of Alzheimer's disease. NeuroImage: Clinical, 2019, 22, 101777.	2.7	29
39	Telemedicine assessment of long-term cognitive and functional status in anti-leucine-rich, glioma-inactivated $1$ encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2020, $7$ , .	6.0	29
40	PICOGEN: experiencia de 5 años de un programa de asesoramiento genético en demencia. NeurologÃa, 2011, 26, 143-149.	0.7	28
41	Longitudinal brain atrophy and CSF biomarkers in early-onset Alzheimer's disease. NeuroImage: Clinical, 2021, 32, 102804.	2.7	28
42	Diagnostic accuracy of behavioral variant frontotemporal dementia consortium criteria (FTDC) in a clinicopathological cohort. Neuropathology and Applied Neurobiology, 2015, 41, 882-892.	3.2	26
43	Structural Connectivity Alterations Along the Alzheimer's Disease Continuum: Reproducibility Across Two Independent Samples and Correlation with Cerebrospinal Fluid Amyloid-β and Tau. Journal of Alzheimer's Disease, 2018, 61, 1575-1587.	2.6	25
44	Rare Variants in <i>PLD3</i> Do Not Affect Risk for Early-Onset Alzheimer Disease in a European Consortium Cohort. Human Mutation, 2015, 36, 1226-1235.	2.5	23
45	Globular glial tauopathy caused by MAPT P301T mutation: clinical and neuropathological findings. Journal of Neurology, 2019, 266, 2396-2405.	3.6	22
46	Contribution of CSF biomarkers to earlyâ€onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures. Human Brain Mapping, 2020, 41, 2004-2013.	3.6	22
47	Going round in circles—The Papez circuit in Alzheimer's disease. European Journal of Neuroscience, 2021, 54, 7668-7687.	2.6	22
48	A novel PSEN1 mutation (K239N) associated with Alzheimer's disease with wide range age of onset and slow progression. European Journal of Neurology, 2010, 17, 994-996.	3.3	21
49	The hippocampal longitudinal axis—relevance for underlying tau and TDP-43 pathology. Neurobiology of Aging, 2018, 70, 1-9.	3.1	21
50	Clinical applicability of diagnostic biomarkers in earlyâ€onset cognitive impairment. European Journal of Neurology, 2019, 26, 1098-1104.	3.3	20
51	Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia. Neurobiology of Aging, 2018, 66, 181.e3-181.e10.	3.1	19
52	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 997-1004.	1.9	19
53	Systematic Screening of Ubiquitin/p62 Aggregates in Cerebellar Cortex Expands the Neuropathological Phenotype of the C9orf72 Expansion Mutation. Journal of Neuropathology and Experimental Neurology, 2018, 77, 703-709.	1.7	18
54	Quantitative Magnetic Resonance Abnormalities in Creutzfeldt-Jakob Disease and Fatal Insomnia. Journal of Alzheimer's Disease, 2016, 55, 431-443.	2.6	17

#	Article	IF	CITATIONS
55	White Matter Abnormalities Track Disease Progression in PSEN1 Autosomal Dominant Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 51, 827-835.	2.6	17
56	Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort. Neurobiology of Aging, 2018, 62, 245.e1-245.e7.	3.1	16
57	Altered Blood Gene Expression of Tumor-Related Genes (PRKCB, BECN1, and CDKN2A) in Alzheimer's Disease. Molecular Neurobiology, 2016, 53, 5902-5911.	4.0	15
58	MAPT gene duplications are not a cause of frontotemporal lobar degeneration. Neuroscience Letters, 2007, 424, 61-65.	2.1	14
59	APPâ€derived peptides reflect neurodegeneration in frontotemporal dementia. Annals of Clinical and Translational Neurology, 2019, 6, 2518-2530.	3.7	13
60	Large APP locus duplication in a sporadic case of cerebral haemorrhage. Neurogenetics, 2014, 15, 145-149.	1.4	12
61	Diagnostic Accuracy of MRI Visual Rating Scales in the Diagnosis of Early Onset Cognitive Impairment. Journal of Alzheimer's Disease, 2020, 73, 1575-1583.	2.6	12
62	Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration. JAMA Network Open, 2021, 4, e211290.	5.9	12
63	Sporadic MM2â€thalamic + cortical Creutzfeldtâ€Jakob disease: Utility of diffusion tensor imaging in the detection of cortical involvement <i>in vivo</i> . Neuropathology, 2016, 36, 199-204.	1.2	11
64	Screening of dementia genes by whole-exome sequencing in Spanish patients with early-onset dementia: likely pathogenic, uncertain significance and risk variants. Neurobiology of Aging, 2020, 93, e1-e9.	3.1	11
65	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. Journal of Alzheimer's Disease, 2017, 56, 543-555.	2.6	10
66	Changes in the sympathetic skin response after thoracoscopic sympathectomy in patients with primary palmar hyperhidrosis. Clinical Neurophysiology, 2005, 116, 1348-1354.	1.5	9
67	Assessing the role of TUBA4A gene in frontotemporal degeneration. Neurobiology of Aging, 2016, 38, 215.e13-215.e14.	3.1	9
68	Cognitive decline in amyotrophic lateral sclerosis: Neuropathological substrate and genetic determinants. Brain Pathology, 2021, 31, e12942.	4.1	9
69	Reduced Levels of miR-342-5p in Plasma Are Associated With Worse Cognitive Evolution in Patients With Mild Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 705989.	3.4	9
70	Spanish-dementia knowledge assessment scale (DKAS-S): psychometric properties and validation. BMC Geriatrics, 2021, 21, 302.	2.7	8
71	Cost-effectiveness of Alzheimer's disease CSF biomarkers and amyloid-PET in early-onset cognitive impairment diagnosis. European Archives of Psychiatry and Clinical Neuroscience, 2023, 273, 243-252.	3.2	8
72	A unique common ancestor introduced P301L mutation in MAPT gene in frontotemporal dementia patients from Barcelona (Baix Llobregat, Spain). Neurobiology of Aging, 2019, 84, 236.e9-236.e15.	3.1	7

#	Article	IF	CITATIONS
73	Novel P397S <i>MAPT</i> variant associated with late onset and slow progressive frontotemporal dementia. Annals of Clinical and Translational Neurology, 2019, 6, 1559-1565.	3.7	6
74	Errorless Learning Therapy in Semantic Variant of Primary Progressive Aphasia. Journal of Alzheimer's Disease, 2021, 79, 415-422.	2.6	6
<b>7</b> 5	Baseline MRI atrophy predicts 2-year cognitive outcomes in early-onset Alzheimer's disease. Journal of Neurology, 2022, 269, 2573-2583.	3.6	6
76	Preservation of cell-survival mechanisms by the presenilin-1 K239N mutation may cause its milder clinical phenotype. Neurobiology of Aging, 2016, 46, 169-179.	3.1	5
77	A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimer's Disease Risk. Journal of Alzheimer's Disease, 2017, 56, 1065-1074.	2.6	5
78	Regional patterns of 18F-florbetaben uptake in presenilin 1 mutation carriers. Neurobiology of Aging, 2019, 81, 1-8.	3.1	5
79	Mitochondrial Dysfunction: A Common Hallmark Underlying Comorbidity between sIBM and Other Degenerative and Age-Related Diseases. Journal of Clinical Medicine, 2020, 9, 1446.	2.4	4
80	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. Alzheimer's and Dementia, 2021, $17$ , .	0.8	4
81	Chemical Stimulation of Rodent and Human Cortical Synaptosomes: Implications in Neurodegeneration. Cells, 2021, 10, 1174.	4.1	3
82	Distinct neuropsychological presentation and progression between early―and lateâ€onset Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e036809.	0.8	1
83	An ABCA7 partial deletion and a GRN variant in a semantic variant of primary progressive aphasia patient. Alzheimer's and Dementia, 2020, 16, e042483.	0.8	1
84	ALTOIDA‡ADL for the diagnosis of Mild Cognitive Impairment and early Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, e057982.	0.8	1
85	P1-253: WHITE MATTER CHANGES IN PRECLINICAL ALZHEIMER'S DISEASE: AN MRI DIFFUSION TENSOR IMAGING STUDY., 2014, 10, P399-P400.		O
86	IC-02-05: Cerebrospinal Fluid Strem2 Levels are Associated with Gray Matter Volume Increases and Reduced Diffusivity in Early Alzheimer's Disease. , 2016, 12, P8-P8.		0
87	[P4–505]: CORTICAL MICROSTRUCTURAL CHANGES IN FRONTOTEMPORAL LOBAR DEGENERATION: A NEW IMAGING BIOMARKER. Alzheimer's and Dementia, 2017, 13, P1533.	0.8	O
88	[P2–355]: CSF STREM2, BUT NOT YKLâ€40, IS ASSOCIATED WITH LONGITUDINAL MORPHOLOGICAL BRAIN CHANGES IN PRECLINICAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P758.	0.8	0
89	[P2–410]: VISUAL AND QUANTITATIVE ASSESSMENT OF HIPPOCAMPAL ATROPHY IN EARLY ONSET ALZHEIMER's DISEASE PATIENTS. Alzheimer's and Dementia, 2017, 13, P789.	0.8	O
90	[P4–214]: TOWARD A FUNCTIONAL NEUROMARKER FOR PRECLINICAL AD: EIGENVECTOR CENTRALITY REVEAL PRECLINICAL DIFFERENCES OF FUNCTIONAL INFORMATION FLOW IN THE HIPPOCAMPUS, PRECUNEUS, CEREBELLUM AND INFERIOR PARIETAL LOBULE. Alzheimer's and Dementia, 2017, 13, P1348.	S 0.8	0

#	Article	IF	CITATIONS
91	[P1–413]: VISUAL PATTERNS OF FLORBETABEN UPTAKE IN PRESENILIN 1 MUTATION CARRIERS. Alzheimer's an Dementia, 2017, 13, P435.	d <sub>0.8</sub>	0
92	P2â€347: THE HIPPOCAMPAL LONGITUDINAL AXIS: RELEVANCE FOR UNDERLYING TAU AND TDPâ€43 PATHOLOGAlzheimer's and Dementia, 2018, 14, P819.	GY 0.8	0
93	P1â€146: WHOLE EXOME SEQUENCING IN PATIENTS WITH EARLYâ€ONSET ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA: MUTATION DETECTION IN CAUSAL AND RISK GENES FOR DEMENTIA. Alzheimer's and Dementia, 2018, 14, P332.	0.8	0
94	P2â€⊋62: A CEREBROSPINAL FLUID PANEL OF SYNAPTIC PROTEINS ACROSS THE ENTIRE ALZHEIMER'S DISEASE CONTINUUM. Alzheimer's and Dementia, 2018, 14, P777.	0.8	0
95	P3â€394: CORTICAL MEAN DIFFUSIVITY MAY BE MORE SENSITIVE IN DETECTING STRUCTURAL CHANGES IN FRONTOTEMPORAL DEMENTIA THAN CORTICAL THICKNESS. Alzheimer's and Dementia, 2018, 14, P1248.	0.8	0
96	P1â€432: REGIONAL PATTERNS OF 18Fâ€FLORBETABEN UPTAKE IN PRESENILIN 1ÂMUTATION CARRIERS. Alzhein and Dementia, 2018, 14, P475.	ner's 0.8	0
97	O3â€09â€03: SERUM NEUROFILAMENT LIGHT LEVELS CORRELATE WITH SEVERITY MEASURES AND NEURODEGENERATION MARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1037.	0.8	0
98	MRI decline pattern in early onset MCI due to Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e037405.	0.8	0
99	Four years' experience in an earlyâ€onset dementia clinic in Barcelona. Alzheimer's and Dementia, 2020, 16, e037911.	0.8	0
100	Evolution of clinicalâ€pathological correlation of earlyâ€onset Alzheimer's disease: 1994–2009 vs 2010–2017. Alzheimer's and Dementia, 2020, 16, e041388.	0.8	0
101	Differential gene expression in genetic and earlyâ€onset Alzheimer's disease in two biological samples: Brain tissue and lymphoblastoid cell lines. Alzheimer's and Dementia, 2020, 16, e042671.	0.8	0
102	Functional network alterations in earlyâ€onset Alzheimer's disease studied with restingâ€state fMRI. Alzheimer's and Dementia, 2020, 16, e043307.	0.8	0
103	Agreement of amyloid PET and CSF biomarkers in a clinical cohort. Alzheimer's and Dementia, 2021, 17, .	0.8	0
104	Impact of COVIDâ€19 pandemic in an earlyâ€onset dementia clinic in Barcelona. Alzheimer's and Dementia, 2021, 17, e052114.	0.8	0